PBH

Prestige Consumer Healthcare Inc. (Prestige Brands Holdings, Inc.) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for the period ended September 30, 2007. Prestige Brands Holdings, Inc. is a holding company engaged in the marketing, sales, and distribution of over-the-counter healthcare, personal care, and household cleaning brands to mass merchandisers, drug stores, and supermarkets primarily in the United States and Canada. The company operates through three segments: Over-the-Counter Healthcare, Household Cleaning, and Personal Care.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 3.3% ($2.8 million) for the quarter and 3.4% ($5.5 million) for the six-month period compared to 2006. Growth was primarily driven by the September 2006 acquisition of the Wartner brand and the launch of Murine Earigate.
• Profitability Decline: Net income decreased 22.3% for the quarter ($6.8 million vs. $8.8 million) and 11.1% for the six-month period ($15.1 million vs. $17.0 million). Operating income declined 14.7% for the quarter and 8.0% for the six-month period.
• Segment Performance:
  • OTC Healthcare: Revenues increased 8.1% (quarter) and 7.7% (six months), driven by Wartner and Murine Earigate.
  • Household Cleaning: Revenues were essentially flat (0.6% increase quarter, -0.1% six months).
  • Personal Care: Revenues declined 16.1% (quarter) and 8.0% (six months) due to declining consumption of major brands like Cutex and Denorex.
• Expense Increases: Advertising and promotion expenses rose 16.6% for the quarter and 11.5% for the six-month period, primarily to support new product launches. General and administrative expenses increased significantly due to higher legal costs related to arbitration and intellectual property litigation.
• Product Withdrawal Impact: The company increased its allowance for returns by $1.1 million due to the voluntary withdrawal of two Little Remedies pediatric cough and cold products pending FDA review. This action reduced reported revenues and gross profit.

Guidance, Outlook, Risks, and Contingencies

• Legal Proceedings:
  • Securities Class Action: A class was certified regarding the 2005 IPO; the company intends to vigorously defend the claims but cannot estimate potential loss.
  • OraSure Arbitration: A partial final award was issued in October 2007. The arbitrators awarded OraSure nominal damages ($1.00) but awarded counsel fees to be determined. The company plans to contest the fees. The distribution agreement terminates December 31, 2007, with no expected supply interruption.
  • DenTek Litigation: The company filed a lawsuit alleging IP infringement and trade secret misappropriation, seeking a preliminary injunction.
• Debt and Liquidity: The company has $437.1 million in outstanding indebtedness. It maintains a leverage ratio of less than 4.5 to 1.0 and is in compliance with all financial covenants. The company has $60.0 million available under its Revolving Credit Facility and $200.0 million available under its Tranche B Term Loan Facility.
• Market Risks: The company is exposed to interest rate fluctuations on its variable-rate debt ($311.1 million). A 1% increase in rates would impact pre-tax earnings by approximately $3.1 million, though interest rate caps limit this exposure. Inflationary pressures on raw materials and transportation costs are also noted risks.
• Outlook: Management expects cash flows from operations and available borrowings to be sufficient to meet obligations for the next 12 months. No specific financial guidance for the full fiscal year was provided in this text.

Key Facts for Investor Verification

• Little Remedies Withdrawal: Verify the status of the FDA safety review and the final financial impact of the $1.1 million return allowance and $800,000 obsolescence charge.
• Legal Fee Exposure: Monitor the determination of counsel fees in the OraSure arbitration, as the company intends to contest the award.
• Personal Care Segment: Assess the sustainability of the revenue decline in the Personal Care segment and the effectiveness of strategies to reverse consumption trends for brands like Cutex and Denorex.
• Debt Servicing: Confirm continued compliance with leverage and interest coverage covenants given the high debt load ($437.1 million) and rising interest rates.
• Supply Chain Transition: Verify the successful transition of the Compound W Freeze Off supply chain following the termination of the OraSure distribution agreement on December 31, 2007.